Raw kratom leaf is naturally variable. Alkaloid content shifts with cultivar, growing region, leaf maturity, harvest timing, drying, and storage — so two batches of "the same" leaf can differ several-fold in potency. For any serious downstream use, that variability is the core problem to solve.
Standardization is the answer. A standardized extract is processed and adjusted so that a defined marker compound is present at a fixed, declared concentration. For Mitragyna speciosa, that marker is mitragynine, the most abundant indole alkaloid in the plant and the one most widely used to characterize it.
What 'standardized to a marker' actually means
When we say an extract is standardized to, for example, a defined mitragynine percentage, we mean the finished material has been assayed and adjusted so the mitragynine mass fraction falls within a tight specification window. The specification is the contract: it states the marker, the target percentage, the acceptable range, and the analytical method used to confirm it.
The analytical backbone is reversed-phase high-performance liquid chromatography (HPLC), in which the extract is compared against a certified mitragynine reference standard. The assay returns a number; that number either meets the spec or the batch is reworked or rejected.
- Marker compound: mitragynine (primary indole alkaloid).
- Specification: declared target % with an upper and lower acceptance limit.
- Method: HPLC against a certified reference standard, with documented system suitability.
- Records: each batch ships with a result tied to a retained sample.
Why it matters for manufacturers and researchers
Consistency is the headline benefit. When the marker is fixed, formulation math becomes predictable: a known input gives a known output, batch after batch. That predictability is what makes precision-dosed formats — capsules, edibles, ready-to-drink beverages — possible at all.
Standardization also creates a defensible quality story. A documented specification, a validated method, and retained samples are the difference between a commodity powder and a material a regulated buyer can qualify, audit, and trust.
VITI's approach
VITI operates a phytoactive biorefinery at the EECi API Facility in Rayong, Thailand. We standardize Mitragyna speciosa extracts to a mitragynine marker, pair each batch with assay results, and supply the material strictly for research and B2B use.
Kratom's legal status varies widely by country and sub-national jurisdiction. Our extracts are standardized inputs, not finished consumer products, and buyers are responsible for confirming that any ingredient is permitted for their intended use in their market.